Thus, the upregulation of HO-1 may provide a potential target for pharmacological intervention in the treatment of patients with diet-induced obesity and metabolic syndrome without side effect. This evidence concerns the gene HMOX1 and obesity due to melanocortin 4 receptor deficiency.